Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma

Single institutional experiences over 8 years

Kosei Matsue, Hideaki Fujiwara, Kan Ichi Iwama, Shun Ichi Kimura, Masayuki Yamakura, Masami Takeuchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival. In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens on the reversibility of renal function, which has not been adequately evaluated previously. We studied the impact on the reversibility of high-dose dexamethasone and/or thalidomide-containing regimen in 12 newly diagnosed MM patients (median 74 years, range; 63-85 years) who required dialysis at Kameda General Hospital from 2001 to 2008. There were seven light chain only myelomas, three IgD myelomas, and two IgG myelomas. Ten patients initially received highdose dexamethasone-based treatment and two received thalidomide-based treatment, with modifications. Complete (CR) and partial responses (PR) were obtained in three and five patients, respectively. Dialysis independency was achieved in all eight patients (67%) who achieved better than PR, with a median duration of 2.0 months. Six of the ten patients who received high-dose dexamethasonecontaining regimen and all of the two patients received thalidomide-containing regimen became dialysis-independent. A high concentration of serum-free light chain was detected in all patients examined, before the start of antimyeloma treatment, and this was associated with the presence of advanced renal failure. Improved renal function was preceded by a significant decrease in serum-free light chain in patients who achieved dialysis independence. These results suggest that dialysis-dependent renal failure is reversible by dexamethasone- or thalidomide-based treatments in most patients with MM, even if the patient is in advanced age, and that serum-free light chain monitoring might be useful for predicting improvements in renal function.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalAnnals of Hematology
Volume89
Issue number3
DOIs
Publication statusPublished - Mar 2010
Externally publishedYes

Fingerprint

Multiple Myeloma
Renal Insufficiency
Dialysis
Thalidomide
Dexamethasone
Light
Kidney
Serum
Therapeutics
Immunoglobulin D
Acute Kidney Injury
General Hospitals
Immunoglobulin G
Survival

Keywords

  • Bortezomib
  • Dialysis
  • Free light chain
  • High-dose dexamethasone
  • Multiple myeloma
  • Renal failure
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma : Single institutional experiences over 8 years. / Matsue, Kosei; Fujiwara, Hideaki; Iwama, Kan Ichi; Kimura, Shun Ichi; Yamakura, Masayuki; Takeuchi, Masami.

In: Annals of Hematology, Vol. 89, No. 3, 03.2010, p. 291-297.

Research output: Contribution to journalArticle

Matsue, Kosei ; Fujiwara, Hideaki ; Iwama, Kan Ichi ; Kimura, Shun Ichi ; Yamakura, Masayuki ; Takeuchi, Masami. / Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma : Single institutional experiences over 8 years. In: Annals of Hematology. 2010 ; Vol. 89, No. 3. pp. 291-297.
@article{35dbda5f594047a8b7aa6ca2011cc3d0,
title = "Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: Single institutional experiences over 8 years",
abstract = "Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival. In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens on the reversibility of renal function, which has not been adequately evaluated previously. We studied the impact on the reversibility of high-dose dexamethasone and/or thalidomide-containing regimen in 12 newly diagnosed MM patients (median 74 years, range; 63-85 years) who required dialysis at Kameda General Hospital from 2001 to 2008. There were seven light chain only myelomas, three IgD myelomas, and two IgG myelomas. Ten patients initially received highdose dexamethasone-based treatment and two received thalidomide-based treatment, with modifications. Complete (CR) and partial responses (PR) were obtained in three and five patients, respectively. Dialysis independency was achieved in all eight patients (67{\%}) who achieved better than PR, with a median duration of 2.0 months. Six of the ten patients who received high-dose dexamethasonecontaining regimen and all of the two patients received thalidomide-containing regimen became dialysis-independent. A high concentration of serum-free light chain was detected in all patients examined, before the start of antimyeloma treatment, and this was associated with the presence of advanced renal failure. Improved renal function was preceded by a significant decrease in serum-free light chain in patients who achieved dialysis independence. These results suggest that dialysis-dependent renal failure is reversible by dexamethasone- or thalidomide-based treatments in most patients with MM, even if the patient is in advanced age, and that serum-free light chain monitoring might be useful for predicting improvements in renal function.",
keywords = "Bortezomib, Dialysis, Free light chain, High-dose dexamethasone, Multiple myeloma, Renal failure, Thalidomide",
author = "Kosei Matsue and Hideaki Fujiwara and Iwama, {Kan Ichi} and Kimura, {Shun Ichi} and Masayuki Yamakura and Masami Takeuchi",
year = "2010",
month = "3",
doi = "10.1007/s00277-009-0813-8",
language = "English",
volume = "89",
pages = "291--297",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma

T2 - Single institutional experiences over 8 years

AU - Matsue, Kosei

AU - Fujiwara, Hideaki

AU - Iwama, Kan Ichi

AU - Kimura, Shun Ichi

AU - Yamakura, Masayuki

AU - Takeuchi, Masami

PY - 2010/3

Y1 - 2010/3

N2 - Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival. In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens on the reversibility of renal function, which has not been adequately evaluated previously. We studied the impact on the reversibility of high-dose dexamethasone and/or thalidomide-containing regimen in 12 newly diagnosed MM patients (median 74 years, range; 63-85 years) who required dialysis at Kameda General Hospital from 2001 to 2008. There were seven light chain only myelomas, three IgD myelomas, and two IgG myelomas. Ten patients initially received highdose dexamethasone-based treatment and two received thalidomide-based treatment, with modifications. Complete (CR) and partial responses (PR) were obtained in three and five patients, respectively. Dialysis independency was achieved in all eight patients (67%) who achieved better than PR, with a median duration of 2.0 months. Six of the ten patients who received high-dose dexamethasonecontaining regimen and all of the two patients received thalidomide-containing regimen became dialysis-independent. A high concentration of serum-free light chain was detected in all patients examined, before the start of antimyeloma treatment, and this was associated with the presence of advanced renal failure. Improved renal function was preceded by a significant decrease in serum-free light chain in patients who achieved dialysis independence. These results suggest that dialysis-dependent renal failure is reversible by dexamethasone- or thalidomide-based treatments in most patients with MM, even if the patient is in advanced age, and that serum-free light chain monitoring might be useful for predicting improvements in renal function.

AB - Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival. In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens on the reversibility of renal function, which has not been adequately evaluated previously. We studied the impact on the reversibility of high-dose dexamethasone and/or thalidomide-containing regimen in 12 newly diagnosed MM patients (median 74 years, range; 63-85 years) who required dialysis at Kameda General Hospital from 2001 to 2008. There were seven light chain only myelomas, three IgD myelomas, and two IgG myelomas. Ten patients initially received highdose dexamethasone-based treatment and two received thalidomide-based treatment, with modifications. Complete (CR) and partial responses (PR) were obtained in three and five patients, respectively. Dialysis independency was achieved in all eight patients (67%) who achieved better than PR, with a median duration of 2.0 months. Six of the ten patients who received high-dose dexamethasonecontaining regimen and all of the two patients received thalidomide-containing regimen became dialysis-independent. A high concentration of serum-free light chain was detected in all patients examined, before the start of antimyeloma treatment, and this was associated with the presence of advanced renal failure. Improved renal function was preceded by a significant decrease in serum-free light chain in patients who achieved dialysis independence. These results suggest that dialysis-dependent renal failure is reversible by dexamethasone- or thalidomide-based treatments in most patients with MM, even if the patient is in advanced age, and that serum-free light chain monitoring might be useful for predicting improvements in renal function.

KW - Bortezomib

KW - Dialysis

KW - Free light chain

KW - High-dose dexamethasone

KW - Multiple myeloma

KW - Renal failure

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=77949329927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949329927&partnerID=8YFLogxK

U2 - 10.1007/s00277-009-0813-8

DO - 10.1007/s00277-009-0813-8

M3 - Article

VL - 89

SP - 291

EP - 297

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -